What this trial studies
This study proposes to assess feasibility and acceptability of screening and risk reducing interventions in individuals at increased for endometrial cancer (EC). The investigators will use an epidemiological risk model to participants' absolute risk of developing EC in the next 10 years. Those whose absolute risk is 2% or greater or who have a Body Mass Index (BMI) higher than 34.9 will proceed to a second screening test (the Progesterone Challenge Test or the PCT) used to identify those with endometrial proliferation. The PCT consists of taking a ten-day course of medroxyprogesterone acetate (Provera) 10 mg per os daily.
Conditions in scope
- Endometrium Cancer
Interventions
- Provera (Drug) — Progesterone Challenge Test
Who can join
Women only · Adults (Child, Adult, Older Adult) · Accepts healthy volunteers.
Inclusion criteria
- Individuals are postmenopausal (must be three (3) years past last menstrual period)
- Individuals have an intact uterus (have not had a hysterectomy)
Exclusion criteria
- Individuals taking hormone therapy for menopause (including vaginal estrogen)
- Individuals taking male hormones,
- Individuals on anti-endocrine therapy (such as tamoxifen)
- Individuals on aromatase inhibitor therapy
- Individuals who have experienced abnormal uterine bleeding
- Individuals who have an Intrauterine Device (IUD)
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Vancouver | British Columbia | VGH Research Pavilion | Unknown |
Status & timeline
- Overall status: Completed
- Study type: Interventional
- Phase: PHASE4
- Start date: 2023-03-15
- Primary completion: 2025-11-30
- Last update posted: 2026-04-13
- First posted: 2022-12-15
Sponsor & contact
Lead sponsor: University of British Columbia (Other)
Collaborators: Canadian Institutes of Health Research (CIHR), Canadian Cancer Society (CCS)
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Feasibility of Proposed Screening Method (Through study completion, an average of 1 year)
Feasibility will be measured through rates of study enrollment, drop out, and adherence to intervention protocol. To be considered feasible, the study must meet all three of the following criteria: (1) enrollment and accruals: at least 80% of individuals in the top 30 percentile for risk will agree to and complete the PCT; (2) retention: at least a 50% overall… - Acceptability of Proposed Screening Method (Through study completion, an average of 1 year)
Acceptability will be measured through a standardized and validated survey of satisfaction with therapeutic services, the Client Satisfaction Questionnaire-8 (CSQ-8). Acceptability will be defined as a group median score ≥28 (scores range from 8 to 32) on the CSQ-8. Program evaluation items will be analyzed descriptively. The investigators will use analysis of variance to determine whether the feasibility or acceptability…
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT05651282 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.